Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Bob Moriarty | It’s Time to Buy Silver!

In this interview, Bob Moriarty of 321gold sits down with Maurice Jackson of Proven and Probable to discuss a number of important topics ranging from hospital cost incentives regarding the COVID-19, and the how the economy...
Maurice Jackson | May 19, 2020 |

Power of Narratives and Gold

The U.S. manufacturing sector has been growing weaker recently, entering recession. How serious is this contraction, and does it have the power to spill over to the broader economy? Let’s turn to gold – how far can these developments take us on the yellow brick...
Arkadiusz Sieron | November 22, 2019 |

Neurotrope's Shares Double on Phase 2 Alzheimer's Study Data and $2.7 Million NIH Grant

Neurotrope's shares traded higher today after reporting results from its Phase 2 "203" clinical trial of Byrostatin-1 for treatment of moderately severe to severe Alzheimer's patients. The firm has also been awarded a $2.7 million grant from the National Institutes of Health t...
Streetwise Reports | January 23, 2020 |

Strong Historical Probability of NG Long Trades Setting Up

Would you believe that March and April, historically, shows a 2 to 1 statistical probability of NG moving higher. Each of these months shows, historically, that NG has a strong potential for at least a $1.00 upside price move in both March and April. Only 1/3 of the historical...
Chris Vermeulen | March 8, 2019 |

Nov 17th 2019, Crypto Chartbook – Indicator divergence

Indicator divergence With a vast following of market speculators, we receive a consistent inflow of questions and comments about the market. Traders ask in our our telegram channel, in which we post our trades live, and via e mail as well as in our public appearances, ab...
Korbinian Koller | November 19, 2019 |

Buzz on the Bullboards: Who’s Who in the Business of COVID

(Stock photo.) It’s another week of the COVID-19 pandemic, which means another week where we see the healthcare sector continue to dominate investor attention … and for good reason. Small-cap investors are always on the lookout for the most curre...
Stockhouse Editorial | October 14, 2020 |

Mining Firm Expands Its Reach with Artificial Intelligenc

Mining Firm Expands Its Reach with Artificial Intelligence Source: Peter Epstein for Streetwise Reports 04/22/2019 Peter Epstein of Epstein Research digs into the potential of this company's AI technology, which he believes offers significant benefits for the stakeh...
Streetwise Reports | April 23, 2019 |

Three More Years of Expansion? How Will Gold React?

We are just a few weeks from breaking the record. If the current US economic expansion lasts until July 2019, it will reach 121 months, becoming the longest ever. The extended duration of the prosperity begs the question of when the next downturn will occur. We invite you to r...
Arkadiusz Sieron | May 27, 2019 |

'Data Readouts Approaching in Two Pivotal Trials' for Biopharma Targeting Unmet Needs

The next steps for each of the programs are outlined in a Dawson James Securities report. In an Aug. 14 research note, Dawson James Securities analyst Jason Kolbert reported that Soligenix Inc. (SNGX:NASDAQ) "is now focused on the two pivotal programs, i...
Streetwise Reports | August 22, 2019 |

Avadel Pharma Shares Up 30% Upon Acceleration of Phase 3 REST-ON Study

Avadel Pharmaceuticals' shares are trading 30% higher today on news that the FDA agreed to reduce the sample size required for its Phase 3 REST-ON study, accelerating its completion by year-end 2019. Dublin, Ireland-based Avadel Pharmaceuticals Plc (AVDL:NASDAQ) , wh...
Streetwise Reports | September 24, 2019 |
1 2 3 4